Interleukin-12 Enhances the Sensitivity of Human Osteosarcoma Cells to 4-Hydroperoxycyclophosphamide by a Mechanism Involving the Fas/Fas-Ligand Pathway

Clinical Cancer Research

Volumn 10, Issue 2, 2004, Pages 777-783

  Duan, Xiaoping ^a   Zhou, Zhichao ^a   Jia, Shu Fang ^a   Colvin, Michael ^b   Lafleur, Elizabeth A ^a   Kleinerman, Eugenie S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b DUKE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; 4 HYDROPEROXYDIDECHLOROCYCLOPHOSPHAMIDE; ALKYLATING AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FAS LIGAND; IFOSFAMIDE; INTERLEUKIN 12; METHOTREXATE; UNCLASSIFIED DRUG;

ARTICLE; CELL DEATH; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; IMMUNOCYTOCHEMISTRY; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SEPARATION; CISPLATIN; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FAS LIGAND PROTEIN; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITORY CONCENTRATION 50; INTERLEUKIN-12; MEMBRANE GLYCOPROTEINS; METHOTREXATE; OSTEOSARCOMA; RNA, MESSENGER; TIME FACTORS; TRANSFECTION; UP-REGULATION;

EID: 0842311594     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-1245-02     Document Type: Article

References (28)

1. Müller, M., Strand, S., Hug, H., Heinemann, E-M., Walczak, H., Hoffman, W. J., Stremmel, W., Krammer, P. H., and Galle, P. R. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Investig., 99: 403-413, 1997.
2. Eichhorst, S. T., Muller, M., Li-Weber, M., Schulze-Bergkamen, H., Angel, P., and Krammer, P. H. A novel ap-1 element in the cd95 ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs. Mol. Cell. Biol., 20: 7826-7837, 2000.
3. Glick, R. D., Swendeman, S. L., Coffey, D. C., Rifkind, R. A., Marks, P. A., Richon, V. M., and La Quaglia, M. P. Hybrid polar histone deacetylase inhibitor induces apoptosis and cd95/cd95 ligand expression in human neuroblastoma. Cancer Res., 59: 4392-4399, 1999.
4. Roth, W., and Weller, M. Chemotherapy and immunotherapy of malignant glioma: molecular mechanisms and clinical perspectives. Cell Mol. Life Sci., 56: 481-506, 1999.
5. Micheau, O., Solary, E., Hammann, A., Martin, F., and Dimanche-Boitrel, M. T. Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity. J. Natl. Cancer Inst. (Bethesda), 89: 783-789, 1997.
6. Backus, H. H., Dukers, D. F., Van Groeningen, C. J., Vos, W., Bloemena, E., Wouters, D., van Riel, J. M., Smid, K., Giaccone, G., Pinedo, H. M., and Peters, G. J. 5-Fluorouracil induced Fas up-regulation associated with apoptosis in liver metastases of colorectal cancer patients. Ann. Oncol., 12: 209-216, 2001.
7. Mitsiades, N., Yu, W. H., Poulaki, V. V., Tsokos, M., and Stamenkovic, I. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res., 61: 577-581, 2001.
8. Lafleur, E. A., Jia, S-F., Worth, L. L., Zhou, Z., Owen-Schaub, L. B., and Kleinerman, E. S. Interleukin (IL)-12 and IL-12 gene transfer up-regulate Fas expression in human osteosarcoma and breast cancer cells. Cancer Res., 61: 4066-4071, 2001.
9. Flowers, J. L., Ludeman, S. M., Gamcsik, M. P., Colvin, O. M., Shao, K-L., Boal, J. B., Springer, J. B., and Adams, D. J. Chloroethylaziridine: a volatile, cytotoxic metabolite of 4-hydroperoxycyclophosphamide. Cancer Chemother. Pharmacol., 45: 335-344, 2000.
10. Worth, L. L., Jia, S-F., Zhou, Z., Chen, L., and Kleinerman, E. S. Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases. Clin. Cancer Res., 6: 3713-3718, 2000.
11. Jia, S-F., and Kleinerman, E. S. Antitumor activity of TNF-α, IL-1, and IFN-γ against three human osteosarcoma cell lines. Lymphokine Cytokine Res., 10: 281-284, 1991.
12. Jia, S-F., An, T., Worth, L. L., and Kleinerman, E. S. Interferon α enhances the sensitivity of human osteosarcoma cells to etoposide. J. Interferon Cytokine Res., 19: 617-624, 1999.
13. Kontny, U., Lehrnbecher, H., Thomas, M., Chanock, S. J., and Mackall, C. L. Simultaneous expression of Fas and nonfunctional Fas ligand in Ewing's sarcoma. Cancer Res., 58: 5842-5849, 1998.
14. Owen-Schaub, L. B., Radinsky, R., Kruzel, E., Berry, K., and Yonehara, S. Anti-Fas on non-hematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res., 54: 1580-1586, 1994.
15. Xiao, N., Hazarika, P., Zhang, C., Talpur, R., and Duvic, M. Fas ligand expression by neoplastic T lymphocytes mediates elimination of cd8 + cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape? Clin. Cancer Res., 7: 2682-2692, 2001.
16. Sata, M., Luo, Z., and Walsh, K. Fas ligand overexpression on allograft endothelium inhibits inflammatory cell infiltration and transplant-associated intimal hyperplasia. J. Immunol., 166: 6964-6971, 2001.
17. Kobayashi, M., Fitz, L., Ryan, M., Hewick, R. M., Clark, S. C., Chan, S., Loudon, R., Sherman, F., Perussia, B., and Trinchieri, G. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes. J. Exp. Med., 170: 827-845, 1989.
18. Gately, M. K., Wolitzky, A. G., Quinn, P. M., and Chizzonite, R. Regulation of human cytolytic lymphocyte responses by interleukin- 12. Cell Immunol., 143: 127-142, 1992.
19. + T cells through IL-12 produced by Listeria-induced macrophages. Science (Wash. DC), 260: 547-549, 1993.
20. Manetti, R., Parronchi, P., Giudizi, M. G., Piccinni, M. P., Maggi, E., Trinchieri, G., and Romagnani, S. Natural killer cell stimulatory factor [interleukin-12 (IL-12)] inducer T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J. Exp. Med., 177: 1199-1204, 1993.
21. Voest, E. E., Kenyon, B. M., O'Reilly, M. S., Truitt, G., D'Amato, R. J., and Folkman, J. Inhibition of angiogenesis in vivo by interleukin-12. J. Natl. Cancer Inst. (Bethesda), 87: 581-586, 1995.
22. Kaufmann, S. H., and Earnshaw, W. C. Induction of apoptosis by cancer chemotherapy. Exp. Cell Res., 256: 42-49, 2000.
23. Fulda, S., Susin, K. A., Kroemer, G., and Debatin, K. M. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res., 58: 4453-4460, 1998.
24. Fulda, S., Los, M., Friesen, C., and Debatin, K. M. Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system. Int. J. Cancer, 76: 105-114, 1998.
25. Houghton, J. A., Harwood, F. G., and Tillman, D. M. Thymineless death in colon carcinoma cells is mediated via Fas signaling. Proc. Natl. Acad. Sci. USA, 94: 8144-8149, 1997.
26. Fulda, S., Scaffidi, C., Pietsch, T., Krammer, P. H., Peter, M. E., and Debatin, K. M. Activation of the CD95 (APO-1/Fas) pathway in drug- and γ-irradiation-induced apoptosis of brain tumor cells. Cell Death Differ., 5: 884-893, 1998.
27. Friesen, C., Fulda, S., and Debatin, K. M. Cytotoxic drugs and the CD95 pathway. Leukemia (Baltimore), 13: 1854-1858, 1999.
28. Friesen, C., Herr, I., Krammer, P. H., and Debatin, K-M. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med., 2: 574-577, 1996.